ACUTE NEUROLOGICAL PROBLEMS: Edited by Peter Le RouxAnticoagulation reversal for intracranial hemorrhage in the era of the direct oral anticoagulantsStrein, Micheala; May, Scottb,c; Brophy, Gretchen M.aAuthor Information aVirginia Commonwealth University, School of Pharmacy, Richmond, Virginia bDepartment of Pharmacy, Connecticut Children's Medical Center cDepartment of Pharmacy, Saint Francis Hospital and Medical Center, Hartford, Connecticut, USA Correspondence to Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FNCS, Pharmacotherapy and Outcomes Science and Neurosurgery, Virginia Commonwealth University, Medical College of Virginia Campus, School of Pharmacy, 410 N. 12th Street, Room 642, Richmond, VA 23298-0533, USA. Tel: +1 804 828 1201; fax: +1 804 828 0343; e-mail: [email protected] Current Opinion in Critical Care: April 2020 - Volume 26 - Issue 2 - p 122-128 doi: 10.1097/MCC.0000000000000706 Buy Metrics Abstract Purpose of review This review focuses on recent relevant literature that examines the reversal of direct oral anticoagulants (DOACs) in patients with intracranial hemorrhage (ICH). The aim of this review is to provide an insightful description of available reversal agents and their clinical utility. Recent findings Increases in prescribing of DOACs has led to the introduction of drug-specific reversal agents. The clinical trials that evaluated these agents did not include a comparator arm making it difficult to determine if they are clinically superior to nonspecific reversal agents. Summary Numerous options for reversal of DOAC-associated ICH are currently available. Recent clinical trials have demonstrated drug-specific reversal agents are effective in this setting, but additional research is needed to determine whether these agents should be routinely preferred over nonspecific reversal agents. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.